Skip to main content

Table 5 Multivariate analysis of DMFS on pretreatment quality of life of QLQ-C30 among 501 patients with nasopharyngeal carcinoma

From: Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT

  HR 95%CI P
Age 1.039 0.560–1.927 0.904
Gender 0.527 0.235–1.183 0.121
Marriage 3.217 0.669–15.479 0.145
Education 1.278 0.967–1.689 0.085
Smoking history 0.731 0.362–1.477 0.383
Alcohol history 0.882 0.342–2.271 0.794
T stage 1.305 0.611–2.787 0.491
N stage 2.251 1.212–4.179 0.010
Pre-treatment EBV DNA 1.730 0.963–3.109 0.067
Post-treatment EBV DNA 2.915 1.338–6.350 0.007
Pain 1.015 0.994–1.038 0.169
Felt ill 1.004 1.000–1.007 0.043
  1. Abbreviations: DMFS Distant metastasis free suvival, HR Harsard ratio